GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and one of the earliest growth hormone secretagogues (GHS) to be discovered and characterized. Developed in the 1980s by Cyril Bowers and colleagues, it was instrumental in the identification and characterization of the GHS receptor (later identified as the ghrelin receptor, GHS-R1a). GHRP-6 acts as a potent agonist at this receptor, stimulating the pituitary gland to release growth hormone in a dose-dependent manner.

GHRP-6 produces robust growth hormone release, typically achieving peak GH levels within 15-30 minutes of administration. However, unlike more selective peptides such as Ipamorelin, GHRP-6 has significant effects on other hormonal axes. It notably stimulates appetite through its strong ghrelin-mimetic activity, and it can increase cortisol and prolactin levels, particularly at higher doses. These additional effects have made it less popular than newer, more selective alternatives for clinical use.

The appetite-stimulating effect of GHRP-6 is one of its most pronounced characteristics. Users commonly report intense hunger within 20-30 minutes of injection, which can last for several hours. While this is generally considered an unwanted side effect for those using it for GH optimization or fat loss, it can be beneficial for individuals who need to increase caloric intake, such as those recovering from illness or those struggling with inadequate appetite.

Research on GHRP-6 has also explored its potential cardioprotective and cytoprotective properties. Studies in animal models have shown that GHRP-6 can protect cardiac tissue from ischemia-reperfusion injury and may have anti-fibrotic effects. Cuban researchers have been particularly active in studying GHRP-6 for wound healing and tissue protection applications, with some clinical investigations in chronic wound management.